A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Inclusion Criteria:

- Have a diagnosis, per World Health Organization (WHO) 2022 criteria of:

1. relapsed/refractory acute myeloid leukemia (AML)

2. relapsed/refractory moderate high, high, or very high risk myelodysplastic neoplasms (MDS) per Molecular International Prognostic Scoring System (IPSS-M)

- Body weight greater than or equals to (>=) 40 kilograms (kg)

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

- Have adequate renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Estimated Glomerular Filtration Rate (eGFR) >=40 milligrams per minute (mL/min)

- Participants must have laboratory parameters in the required range

Exclusion Criteria:

- Has a medical history of clinically significant pulmonary compromise, particularly the need for current supplemental oxygen use to maintain adequate oxygenation

- Has evidence of an uncontrolled systemic viral, bacterial, or fungal infection

- Has known allergies, hypersensitivity, or intolerance to the excipients of JNJ-89853413

- Had major surgery or had significant traumatic injury within 14 days of planned first dose of JNJ-89853413

- Has known active central nervous system involvement